1422435-39-9

Upstream product

• 1427571-33-2 C₂₁H₂₄N₄O₃*ClH 
• 42288-26-6 (4-cyanophenyl)glycine 
• 212322-56-0 ethyl 3-{[{2-amino-1-(methylamino)phen-4-yl}carbonyl](pyridyn-2-yl)amino}propanoate 
• 1422469-70-2 ethyl 3-[[2-[(4-cyanophenylamino)methyl]-1-methyl-1H-benzimidazole-5-carbonyl]pyridin-2-yl-amino]propionate succinic acid 
• 64-17-5 ethanol 
• 211915-84-3 3-[[[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propionic acid ethyl ester 

Downstream Products

• 1408238-36-7 ethyl 2-[[4-[(n-hexyloxycarbonyl)aminoiminomethyl]phenylamino]methyl]-1-methyl-1H-benzimidazole-5-carboxylate 

Relevant academic research and scientific papers

Synthesis, characterization and suppression of impurities during optimization of dabigatran etexilate

The synthetic methods for two impurities of dabigatran etexilate are firstly described, and both of two impurities are characterized by NMR and MS spectral data. The suppression of impurities as well as the optimization process of dabigatran etexilate is also disclosed.

NOVEL REFERENCE MARKERS OF DABIGATRAN ETEXILATE

A new method of obtaining chemically pure and pharmaceutically acceptable Dabigatran Etexilate or its pharmaceutical acceptable salt having purity at least about 99% is provided, wherein the content of Dabigatran Etexilate individual impurity is less than 0.03-0.15% as measured by HPLC. A method of removing specific impurities that are generated either due to the intrinsic instability of Dabigatran Etexilate or in process of its preparation is provided too.